• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

随机和非随机设计在罕见疾病纵向数据中的因果推断。

Randomized and non-randomized designs for causal inference with longitudinal data in rare disorders.

机构信息

Division of Biostatistics and Study Methodology, Children's Research Institute at Children's National Medical Center, The George Washington University, Washington, DC, USA.

出版信息

Orphanet J Rare Dis. 2021 Nov 23;16(1):491. doi: 10.1186/s13023-021-02124-5.

DOI:10.1186/s13023-021-02124-5
PMID:34814939
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8609847/
Abstract

In the United States, approximately 7000 rare diseases affect 30 million patients, and only 10% of these diseases have existing therapies. Sound study design and causal inference methods are essential to demonstrate the therapeutic efficacy, safety, and effectiveness of new therapies. In the rare diseases setting, several factors challenge the use of typical parallel control designs: the small patient population size, genotypic and phenotypic diversity, and the complexity and incomplete understanding of the disorder's progression. Repeated measures, when spaced appropriately relative to disease progression and exploited in design and analysis, can increase study power and reduce variability in treatment effect estimation. This paper reviews these longitudinal designs and draws the parallel between some new and existing randomized studies in rare diseases and their less well-known controlled observational study designs. We show that self-controlled randomized crossover and N-of-1 designs have similar considerations as the observational case series and case-crossover designs. Also, randomized sequential designs have similar considerations to longitudinal cohort studies using sequential matching or weighting to control confounding. We discuss design and analysis considerations for valid causal inference and illustrate them with examples of analyses in multiple rare disorders, including urea cycle disorder and cystic fibrosis.

摘要

在美国,约有 7000 种罕见疾病影响着 3000 万名患者,而这些疾病中仅有 10%存在现有疗法。合理的研究设计和因果推断方法对于证明新疗法的治疗效果、安全性和有效性至关重要。在罕见疾病领域,一些因素对典型平行对照设计的应用提出了挑战:患者人群规模小、基因型和表型多样性、疾病进展的复杂性和不完全了解。适当间隔的重复测量,在设计和分析中加以利用,可以提高研究效能并减少治疗效果估计的变异性。本文综述了这些纵向设计,并将一些新的和现有的罕见病随机研究与不太为人知的对照观察性研究设计进行了比较。我们表明,自我对照随机交叉设计和 N-of-1 设计与观察性病例系列和病例交叉设计具有相似的考虑因素。此外,随机序贯设计与使用序贯匹配或加权来控制混杂因素的纵向队列研究具有相似的考虑因素。我们讨论了用于有效因果推断的设计和分析考虑因素,并通过多种罕见疾病(包括尿素循环障碍和囊性纤维化)的分析示例进行了说明。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/378b/8609847/7ba674c818b9/13023_2021_2124_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/378b/8609847/9e4a322091c5/13023_2021_2124_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/378b/8609847/7ba674c818b9/13023_2021_2124_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/378b/8609847/9e4a322091c5/13023_2021_2124_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/378b/8609847/7ba674c818b9/13023_2021_2124_Fig2_HTML.jpg

相似文献

1
Randomized and non-randomized designs for causal inference with longitudinal data in rare disorders.随机和非随机设计在罕见疾病纵向数据中的因果推断。
Orphanet J Rare Dis. 2021 Nov 23;16(1):491. doi: 10.1186/s13023-021-02124-5.
2
Study Designs for Extending Causal Inferences From a Randomized Trial to a Target Population.从随机试验到目标人群推广因果推论的研究设计。
Am J Epidemiol. 2021 Aug 1;190(8):1632-1642. doi: 10.1093/aje/kwaa270.
3
Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.流行病学方法与应用概述:观察性研究设计的优势与局限性。
Crit Rev Food Sci Nutr. 2010;50 Suppl 1(s1):10-2. doi: 10.1080/10408398.2010.526838.
4
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
5
Evaluation and validation of social and psychological markers in randomised trials of complex interventions in mental health: a methodological research programme.心理健康复杂干预随机试验中社会和心理标志物的评估与验证:一项方法学研究计划。
Health Technol Assess. 2015 Nov;19(93):1-115, v-vi. doi: 10.3310/hta19930.
6
Innovative research methods for studying treatments for rare diseases: methodological review.罕见病治疗研究的创新方法:方法学综述
BMJ. 2014 Nov 24;349:g6802. doi: 10.1136/bmj.g6802.
7
Evaluating longitudinal markers under two-phase study designs.评估两阶段研究设计下的纵向标志物。
Biostatistics. 2019 Jul 1;20(3):485-498. doi: 10.1093/biostatistics/kxy013.
8
On design considerations and randomization-based inference for community intervention trials.关于社区干预试验的设计考量及基于随机化的推断
Stat Med. 1996 Jun 15;15(11):1069-92. doi: 10.1002/(SICI)1097-0258(19960615)15:11<1069::AID-SIM220>3.0.CO;2-Q.
9
Observational designs in clinical multiple sclerosis research: Particulars, practices and potentialities.临床多发性硬化症研究中的观察性设计:细节、实践和潜力。
Mult Scler Relat Disord. 2019 Oct;35:142-149. doi: 10.1016/j.msard.2019.07.006. Epub 2019 Jul 20.
10
Sample Size Estimation in Clinical Research: From Randomized Controlled Trials to Observational Studies.临床研究中的样本量估计:从随机对照试验到观察性研究
Chest. 2020 Jul;158(1S):S12-S20. doi: 10.1016/j.chest.2020.03.010.

引用本文的文献

1
Increased Survival in Patients With Molybdenum Cofactor Deficiency Type A Treated With Cyclic Pyranopterin Monophosphate.接受环磷酸吡哆醛治疗的A型钼辅因子缺乏症患者生存率提高。
J Inherit Metab Dis. 2025 Mar;48(2):e70000. doi: 10.1002/jimd.70000.
2
Evaluating the Practicality of Causal Inference From Non-randomized Observational Data in Small-Scale Clinical Settings: A Study on the Effects of Ninjin'yoeito.评估小规模临床环境中从非随机观察数据进行因果推断的实用性:关于人参养荣汤效果的研究
Cureus. 2024 Mar 8;16(3):e55825. doi: 10.7759/cureus.55825. eCollection 2024 Mar.
3
Exploring human biology with N-of-1 clinical trials.

本文引用的文献

1
The Patient-Centered Outcomes Research Network Antibiotics and Childhood Growth Study: Implementing Patient Data Linkage.患者为中心的结局研究网络抗生素与儿童生长研究:实施患者数据链接。
Popul Health Manag. 2020 Dec;23(6):438-444. doi: 10.1089/pop.2019.0089. Epub 2019 Dec 17.
2
Statistical considerations for rare diseases drug development.罕见病药物研发的统计学考量
J Biopharm Stat. 2019;29(5):874-886. doi: 10.1080/10543406.2019.1657441. Epub 2019 Aug 27.
3
Clustered randomized controlled trial of a clinic-based problem-solving intervention to improve adherence in adolescents with cystic fibrosis.
通过单病例临床试验探索人类生物学。
Camb Prism Precis Med. 2023;1. doi: 10.1017/pcm.2022.15. Epub 2023 Jan 10.
4
Novel clinical trial design and analytic methods to tackle challenges in therapeutic development in rare diseases.应对罕见病治疗研发挑战的新型临床试验设计与分析方法。
Ann Transl Med. 2022 Sep;10(18):1034. doi: 10.21037/atm-21-5496.
基于诊所的问题解决干预对改善囊性纤维化青少年依从性的聚类随机对照试验。
J Cyst Fibros. 2019 Nov;18(6):879-885. doi: 10.1016/j.jcf.2019.05.004. Epub 2019 May 15.
4
Orphan drugs: major development challenges at the clinical stage.孤儿药:临床阶段的主要开发挑战。
Drug Discov Today. 2019 Mar;24(3):867-872. doi: 10.1016/j.drudis.2019.01.005. Epub 2019 Jan 15.
5
Rare disease registries: potential applications towards impact on development of new drug treatments.罕见病登记处:对新药治疗开发影响的潜在应用。
Orphanet J Rare Dis. 2018 Sep 5;13(1):154. doi: 10.1186/s13023-018-0836-0.
6
Lessons learned from IDeAl - 33 recommendations from the IDeAl-net about design and analysis of small population clinical trials.从 IDeAl 中吸取的教训——IDeal-net 关于小人群临床试验设计和分析的 33 条建议。
Orphanet J Rare Dis. 2018 May 11;13(1):77. doi: 10.1186/s13023-018-0820-8.
7
Newborn screening for proximal urea cycle disorders: Current evidence supporting recommendations for newborn screening.新生儿近端尿素循环障碍筛查:支持新生儿筛查建议的现有证据。
Mol Genet Metab. 2018 Jun;124(2):109-113. doi: 10.1016/j.ymgme.2018.04.006. Epub 2018 Apr 20.
8
Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial.培加酶用于治疗苯丙酮尿症:一项关键性、双盲、随机停药的 3 期临床试验。
Mol Genet Metab. 2018 May;124(1):20-26. doi: 10.1016/j.ymgme.2018.03.003. Epub 2018 Mar 18.
9
A novel Blind Start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease.一项用于研究 vestronidase alfa 治疗黏多糖贮积症 VII 的新型盲法启动研究设计,黏多糖贮积症 VII 是一种超罕见的遗传疾病。
Mol Genet Metab. 2018 Apr;123(4):488-494. doi: 10.1016/j.ymgme.2018.02.006. Epub 2018 Feb 12.
10
Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling.边缘结构模型显示环磷酰胺治疗重症幼年皮肌炎的疗效和安全性。
Arthritis Rheumatol. 2018 May;70(5):785-793. doi: 10.1002/art.40418. Epub 2018 Mar 25.